Single User
£4350
PDF
104 pages

MPS-II (Hunter Syndrome) Forecast in 26 Major Markets 2017-2027


Mucopolysaccharidosis-II, also known as MPS-II or Hunter syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. MPS II is caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase (IDS gene) leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues and organs. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.

Unlike other MPS disorders, MPS-II nearly exclusively affects males since it is an X-linked disorder. Few cases of females have been noted; however these cases tend to milder and very rare. MPS-II is typically classified as Severe (with neurological / cognitive impairment) or attenuated / mild (without neurological / cognitive impairment).

This report provides the current prevalent population for MPS-II across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Brazil, Mexico, Japan, South Korea, China, India, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Portugal, Bulgaria, Poland, Estonia, Russia and Czech Republic) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of MPS-II have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPS-II include:

  • Severe airway obstruction
  • Skeletal deformities
  • Cardiomyopathy
  • Neurological decline
  • Hearing loss and otitis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global MPS-II market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of MPS-II and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on MPS-II prevalent population.
  • Identify sub-populations within MPS-II which require treatment.
  • Gain an understanding of the specific markets that have the largest number of MPS-II patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for MPS-II
    • Main Subtype
  • Features of MPS-II patients
    • Hearing status and deafness
    • CNS Features and involvement
    • Skeletal Features and involvement
    • Cardiovascular Features and involvement
    • Other Comorbid Features of MPS-II Patients
    • Surgical Interventions in MPS-II Patients
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
  List of Tables
  • Prevalence of MPS-II, males (000s)
  • MPS-II patients by severity, males (000s)
  • WHO Hearing Impairment Grading
  • Hearing status in MPS-II patients, males (000s)
  • MPS-II patients with CNS involvement, males (000s)
  • MPS-II patients with hydrocephalus, males (000s)
  • MPS-II patients with history of seizure, males (000s)
  • MPS-II patients with behavioural problems, males (000s)
  • MPS-II patients with cognitive problems, males (000s)
  • MPS-II patients with hyperactivity, males (000s)
  • MPS-II patients with gait problems, males (000s)
  • MPS-II patients with decreased muscle strength, males (000s)
  • MPS-II patients with decreased sensation, males (000s)
  • MPS-II patients with difficulty swallowing, males (000s)
  • MPS-II patients with chewing problems, males (000s)
  • MPS-II patients with CTS, males (000s)
  • MPS-II patients with fine motor skill impairment, males (000s)
  • MPS-II patients with Skeletal involvement, males (000s)
  • MPS-II patients with Kyphosis/Scoliosis, males (000s)
  • MPS-II patients with Joint stiffness, males (000s)
  • MPS-II patients with Claw hand, males (000s)
  • MPS-II patients with spine involvement, males (000s)
  • MPS-II patients with shoulder involvement, males (000s)
  • MPS-II patients with elbow involvement, males (000s)
  • MPS-II patients with hand involvement, males (000s)
  • MPS-II patients with hip involvement, males (000s)
  • MPS-II patients with knee involvement, males (000s)
  • MPS-II patients with ankle involvement, males (000s)
  • MPS-II patients with any cardiovascular involvement, males (000s)
  • MPS-II patients with valve disease, males (000s)
  • Type of valve disease, males (000s)
  • MPS-II patients with heart murmur, males (000s)
  • MPS-II patients with cardiomyopathy, males (000s)
  • MPS-II patients with tachycardia, males (000s)
  • MPS-II patients with bradycardia, males (000s)
  • MPS-II patients with arrhythmia, males (000s)
  • MPS-II patients with hypertension, males (000s)
  • MPS-II patients with CHF, males (000s)
  • MPS-II patients with MI event, males (000s)
  • MPS-II patients with PDV, males (000s)
  • MPS-II patients with pebbly skin, males (000s)
  • MPS-II patients with hernias, males (000s)
  • MPS-II patients with otitis, males (000s)
  • MPS-II patients with nasal obstruction, males (000s)
  • MPS-II patients with enlarged liver/spleen, males (000s)
  • MPS-II patients undergoing hernia repair, males (000s)
  • MPS-II patients undergoing tympanostomy, males (000s)
  • MPS-II patients undergoing adenoidectomy, males (000s)
  • MPS-II patients undergoing tonsillectomy, males (000s)
  • MPS-II patients undergoing carpal tunnel release, males (000s)
  • MPS-II patients undergoing dental procedures, males (000s)
  • MPS-II patients undergoing ICS insertion/reversion, males (000s)
  • MPS-II patients undergoing tracheotomy, males (000s)
  • MPS-II patients undergoing trigger finger release, males (000s)
  • MPS-II patients undergoing spinal decompression, males (000s)
  • MPS-II patients undergoing feeding tube insertion, males (000s)
  • MPS-II patients undergoing valve replacement/repair, males (000s)
  • MPS-II patients undergoing spine fusion, males (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Canada Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • France Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Germany Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Italy Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Spain Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • UK Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Ireland Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Brazil Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Mexico Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Japan Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • South Korea Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • China Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • India Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Australia Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Denmark Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Sweden Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Norway Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Turkey Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Portugal Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Bulgaria Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Poland Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Estonia Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Russia Prevalence of MPS-II by 5-yr age cohort, males (000s)
  • Czech Republic Prevalence of MPS-II by 5-yr age cohort, males (000s)
Australia, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, France, Germany, India, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Republic of Korea, Russian Federation, Spain, Sweden, Turkey, United Kingdom, United States of America